Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.01, 8.01, 9.01 · 8-K

InspireMD Inc.

NSPRNASDAQEQUITYCurrent

Entry into a Material Definitive Agreement · Other Events

Item 1.01 Entry into a Material Definitive Agreement. On November 13, 2026, InspireMD, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten public offe…

Filed Nov 16, 2026Accepted Nov 16, 2026, 7:05 AM ESTCIK 1433607Accession 0001493152-26-051997
Share

Company context

InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.

Current securities

Historical securities (4)

Recent company filings

  1. Other EventsNov 20, 2026
  2. 4 filingNov 17, 2026
  3. 4 filingNov 17, 2026
  4. 10-Q filingNov 16, 2026
  5. 424B5 filingNov 16, 2026

Registered securities in this filing

InspireMD, Inc. · 8-K · Filed 2026-11-16

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol
NSPR
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-11-13

Dimensions: Not supplied

Accession 000149315226051997 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 1.01, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement. On November 13, 2026, InspireMD, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “Offering”) of (i) 7,342,308 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and pre-funded warrants to purchase up to 50,350,000 shares of Common Stock (the “Pre-Funded Warrants”), and (ii) accompanying Series L warrants to purchase up to 43,269,231 shares of Common Stock (or, at the election of the holder, pre-funded warrants to purchase up to an equal number of shares of Common Stock in lieu thereof) (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants”), representing 75% of the aggregate number of Shares and Pre-Funded Warrants sold in the Offering. Each Share is being sold together with an accompanying Common Warrant at a combined public offering price of $0.65, and each Pre-Funded Warrant is being sold together with an accompanying Common Warrant at a combined public offering price of $0.6499, which equals the combined public offering price per Share and accompanying Common Warrant, minus $0.0001. Pursuant to the Underwriting Agreement, the Company has agreed to pay the Underwriters an underwriting discount equal to 6.0% of the gross proceeds of the Offering. All of the securities in the Offering are being sold by the Company. Pursuant to the Underwriting Agreement, the Company also agreed to reimburse the Representative for certain expenses up to $125,000. The Underwriting Agreement contains customary representations, warranties and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties. Pursuant to the Underwriting Agreement, and subject to certain exceptions, the Company has agreed not to issue or sell any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock for a period beginning on the date of the Underwriting Agreement and ending 60 days following the closing of the Offering, and not to effect or enter into any variable rate transactions for a period beginning on the date of the Underwriting Agreement and ending six months following the closing of the Offering, in each case without the prior written consent of the Representative. In addition, the Company’s executive officers and directors have agreed, subject to certain exceptions, not to sell or transfer any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock for a period of 60 days from the date of the Underwriting Agreement without the prior written consent of the Representative. The Company also granted the Representative a 30-day option to purchase up to 8,653,846 additional shares of Common Stock and/or Pre-Funded Warrants to purchase up to 8,653,846 shares of Common Stock and/or Common Warrants to purchase up to 6,490,384 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) (or any combination thereof) at the applicable public offering price minus underwriting discounts and commissions, representing 15% of the total number of shares of Common Stock, Pre-Funded Warrants and Common Warrants sold in the Offering, solely to cover over-allotment, if any. Each Pre-Funded Warrant has an exercise price of $0.0001 per share of Common Stock, is immediately exercisable upon issuance and may be exercised at any time until exercised in full. Each Common Warrant has an exercise price of $0.65 per share of Common Stock, is immediately exercisable upon issuance, will expire one year from the date of issuance and may be exercised, at the holder’s election, for Pre-Funded Warrants in lieu of shares of Common Stock. A holder may not exercise any portion of its Warrants to the extent that the holder, together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding Common Stock immediately after exercise. The Common Warrants will be issued pursuant to a warrant agency agreement, dated as of November 12, 2026 (the “Warrant Agency Agreement”), by and between the Company and Securities Transfer Corporation, as warrant agent. The Company estimates that the gross proceeds of the Offering will be approximately $37.5 million (or approximately $43.1 million if the Representative exercises its option to purchase additional securities in full), prior to deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Warrants. The Company intends to use the net proceeds from the Offering for the Company’s operations, including, but not limited to, research and development, sales and marketing, working capital and other general corporate purposes. The closing of the Offering is expected to occur on or about November 16, 2026, subject to the satisfaction or waiver of customary closing conditions. The Offering is being made pursuant to the Company’s effective shelf registration statement on Form S-3 (No. 333-286309), filed with the Securities and Exchange Commission (“SEC”) on April 1, 2025, which became effective on April 10, 2025, and the base prospectus included therein (the “Registration Statement”), as supplemented by preliminary prospectus supplement, dated November 12, 2026, which was filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), and a final prospectus supplement, dated November 13, 2026, relating to and describing the terms of the Offering will be filed with the SEC pursuant to Rule 424(b) under the Securities Act on November 16, 2026. The Underwriting Agreement, the form of Pre-Funded Warrant, the form of Common Warrant and the Warrant Agency Agreement are filed as Exhibits 1.1, 4.1, 4.2 and 4.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The foregoing descriptions of the terms of the Underwriting Agreement, the Pre-Funded Warrants, the Common Warrants and the Warrant Agency Agreement are qualified in their entirety by reference to such exhibits. A copy of the opinion, including the related consent, of Greenberg Traurig, P.A. relating to the legality of the issuance and sale of the securities in the Offering is filed as Exhibit 5.1 hereto.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. On November 13, 2026, the Company issued a press release to announce the pricing of the Offering (the “Pricing Press Release”). A copy of the Pricing Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Forward Looking Statements This Current Report on Form 8-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example, this Current Report on Form 8-K states that the Offering is expected to close on or about November 16, 2026. In fact, the closing of the Offering is subject to various conditions and contingencies as are customary in underwritten public offerings in the United States. If these conditions are not satisfied or the specified contingencies do not occur, this Offering may not close. In addition, forward looking statements in this Current Report on Form 8-K also include the intended use of proceeds from the Offering. For this reason, among others, you should not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this Current Report.
Filed exhibits (4)
EX-4.1 (by filename) ex4-1.htm

Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK INSPIREMD, INC. Warrant Shares: [●] Initial Exercise Date: November 16, 2026 ───────────────────────────────────────────────────────────── THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “ Warrant ”) certifies that, for value received, [●] or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “ Initial Exercise Date ”) until this Warrant is exercised in full (the “ Termination Date ”) but not thereafter, to subscribe for and purchase from InspireMD, Inc., a Delaware corporation (the “ Company ”), up to [●] shares (as subject to adjustment hereunder, the “ Warrant Shares ”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1: “ Affiliate ” means any Person that, directly or indirectly through one or more …

Open exhibit ↗
EX-4.2 (by filename) ex4-2.htm

Exhibit 4.2 SERIES L WARRANT TO PURCHASE COMMON STOCK INSPIREMD, INC. Warrant Shares: _______ Issuance Date: November 16, 2026 ──────────────────────────────────────────────────────── THIS SERIES L WARRANT TO PURCHASE COMMON STOCK (the “ Warrant ”) certifies that, for value received, [●] or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after November 16, 2026 (the “ Initial Exercise Date ”) and on or prior to 5:00 p.m. (New York City time) on November 16, 2027 (the “ Termination Date ”), but not thereafter, to subscribe for and purchase from InspireMD, Inc., a Delaware corporation (the “ Company ”), up to [●] shares (as subject to adjustment hereunder, the “ Warrant Shares ”) of Common Stock or Pre-Funded Warrants (as defined below) to purchase the same number of Warrant Shares (as subject to adjustment as provided herein). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Section 1. Definitions. In addition to the terms defined elsewhere in thi…

Open exhibit ↗
EX-4.3 (by filename) ex4-3.htm

Exhibit 4.3 WARRANT AGENCY AGREEMENT THIS WARRANT AGENCY AGREEMENT (this “Agreement”), dated as of November 12, 2026, is entered into by and between InspireMD, Inc., a Delaware corporation (the “Company”), and Securities Transfer Corporation, a Texas corporation (the “Warrant Agent”). WHEREAS, the Company has filed with the Securities and Exchange Commission a Registration Statement on Form S-3, No: 333-286309 (the “Registration Statement”), for the registration, under the Securities Act of 1933, as amended (the “Act”), of, among other securities, (i) pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”), (ii) Series L warrants to purchase shares of Common Stock or Pre-Funded Warrants in lieu thereof (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”), and (iii) the shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) issuable upon exercise of the Warrants; WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer, exchange and exercise of the Warrants; WHEREAS, t…

Open exhibit ↗
EX-99.1 (by filename) ex99-1.htm

Exhibit 99.1 InspireMD Announces Pricing of $37.5 Million Public Offering Miami, FL -- November 13, 2026 - InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing of its previously announced underwritten public offering of (i) 7,342,308 shares of its common stock, (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase 50,350,000 shares of its common stock, and (iii) accompanying common warrants to purchase 43,269,231 shares of its common stock (or pre-funded warrants in lieu thereof). All securities in the offering are being offered by InspireMD. In addition, the Company granted the underwriters a 30-day option to purchase additional 8,653,846 shares of the Company’s common stock and/or 8,653,846 pre-funded warrants and/or additional common stock warrants to purchase 6,490,384 shares of common stock (or pre-funded warrants in lieu thereof) (or any combination thereof), representing 15% of the total number of shares of common stock and pre-funded warrants sold in the offering, solely to cover over-allotments, if any. The offering is exp…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.